Document:

EXHIBIT
10.1

 

PLAN
OF MERGER

OF

ICTV
HOLDINGS, INC.

INTO

ICTV
BRANDS INC.

 

This
Plan of Merger is adopted by ICTV Brands Inc., a Nevada corporation (the “Company”), as of November 16, 2017
to merge the Company’s wholly-owned subsidiary, ICTV Holdings, Inc., a Nevada corporation (“ICTV Holdings”),
with and into the Company (the “Merger”) in accordance with Section 92A.180 of the Nevada Revised Statutes
(the “NRS”).

 

1.
Merger. In accordance with Section 92A.180 of the NRS, at the Effective Time (as defined below), ICTV Holdings shall be
merged with and into the Company in accordance with this Plan of Merger, and the separate corporate existence of ICTV Holdings
shall thereupon cease. Pursuant to and simultaneously upon the consummation of the Merger at the Effective Time, in accordance
with the NRS, (a) the Company shall continue as the surviving corporation in the Merger (sometime hereinafter referred to as the
“Surviving Corporation”), (b) the corporate identity, existence, powers, rights and immunities of the Company
as the Surviving Corporation shall continue unimpaired by the Merger, and (c) the Company shall succeed to and shall possess all
the assets, properties, rights, privileges, powers, franchises, immunities and purposes, and be subject to all the debts, liabilities,
obligations, restrictions and duties of ICTV Holdings, all without further act or deed.

 

2.
Filing of Articles of Merger; Effective Time. The Merger shall be effective at the time as provided in the Articles of
Merger to be filed with the Secretary of State of the State of Nevada, which filing shall be made as soon as practicable after
the date hereof. The time of such effectiveness shall herein be referred to as the “Effective Time.”

 

3.
Articles of Incorporation of Surviving Corporation. From and after the Effective Time, the Articles of Incorporation of
Company in effect immediately prior to the Effective Time shall be the Articles of Incorporation of the Surviving Corporation,
and shall continue in full force and effect until amended in accordance with the provisions provided therein or the applicable
provisions of the NRS.

 

4.
Bylaws of Surviving Corporation. From and after the Effective Time, the Bylaws of the Company in effect immediately prior
to the Effective Time shall be the Bylaws of the Surviving Corporation, and shall continue in full force and effect until amended
in accordance with the provisions provided therein or the applicable provisions of the NRS.

 

5.
Directors and Officers of Surviving Corporation. From and after the Effective Time, the directors and officers of the Company
immediately prior to the Effective Time shall be the directors and officers of the Surviving Corporation, each such director or
officer to serve in such capacity until his or her earlier death, resignation or removal or until his or her successor is duly
elected or appointed.

 

    	 

    	 

    

 

6.
Effect of Merger on Capital Stock. At the Effective Time, all shares of capital stock of ICTV Holdings issued to the Company
shall be cancelled and extinguished. The capital stock of the Company issued and outstanding immediately prior to the Effective
Time shall be unchanged and remain issued and outstanding immediately after consummation of the Merger.

 

7.
Amendment, Abandonment or Deferral. This Plan of Merger may be amended by the Board of Directors of the Company at any
time prior to the Effective Time. At any time before the Effective Time, this Plan of Merger may be terminated and the Merger
may be abandoned, or the consummation of the Merger may be deferred for a reasonable period of time if, in the opinion of the
Board of Directors of the Company, such action would be in the best interests of the Company. In the event of termination of this
Plan of Merger, this Plan of Merger shall become void and of no effect.

 

This
Plan of Merger has been adopted as of the date set forth above.

 

	 	ICTV
    Brands Inc.
	 	 	 
	 	By:	/s/
    Kelvin Claney
	 	Name:	Kelvin
    Claney
	 	Title:	Chief
    Executive OfficerEXHBIIT
10.2

 

PLAN
OF MERGER

OF

ERMIS
LABS, INC.

INTO

ICTV
BRANDS INC.

 

This
Plan of Merger is adopted by ICTV Brands Inc., a Nevada corporation (the “Company”), as of November 16, 2017
to merge the Company’s wholly-owned subsidiary, Ermis Labs, Inc., a Nevada corporation (“Ermis Labs”),
with and into the Company (the “Merger”) in accordance with Section 92A.180 of the Nevada Revised Statutes
(the “NRS”).

 

1.
Merger. In accordance with Section 92A.180 of the NRS, at the Effective Time (as defined below), Ermis Labs shall be merged
with and into the Company in accordance with this Plan of Merger, and the separate corporate existence of Ermis Labs shall thereupon
cease. Pursuant to and simultaneously upon the consummation of the Merger at the Effective Time, in accordance with the NRS, (a)
the Company shall continue as the surviving corporation in the Merger (sometime hereinafter referred to as the “Surviving
Corporation”), (b) the corporate identity, existence, powers, rights and immunities of the Company as the Surviving
Corporation shall continue unimpaired by the Merger, and (c) the Company shall succeed to and shall possess all the assets, properties,
rights, privileges, powers, franchises, immunities and purposes, and be subject to all the debts, liabilities, obligations, restrictions
and duties of Ermis Labs, all without further act or deed.

 

2.
Filing of Articles of Merger; Effective Time. The Merger shall be effective at the time as provided in the Articles of
Merger to be filed with the Secretary of State of the State of Nevada, which filing shall be made as soon as practicable after
the date hereof. The time of such effectiveness shall herein be referred to as the “Effective Time.”

 

3.
Articles of Incorporation of Surviving Corporation. From and after the Effective Time, the Articles of Incorporation of
Company in effect immediately prior to the Effective Time shall be the Articles of Incorporation of the Surviving Corporation,
and shall continue in full force and effect until amended in accordance with the provisions provided therein or the applicable
provisions of the NRS.

 

4.
Bylaws of Surviving Corporation. From and after the Effective Time, the Bylaws of the Company in effect immediately prior
to the Effective Time shall be the Bylaws of the Surviving Corporation, and shall continue in full force and effect until amended
in accordance with the provisions provided therein or the applicable provisions of the NRS.

 

5.
Directors and Officers of Surviving Corporation. From and after the Effective Time, the directors and officers of the Company
immediately prior to the Effective Time shall be the directors and officers of the Surviving Corporation, each such director or
officer to serve in such capacity until his or her earlier death, resignation or removal or until his or her successor is duly
elected or appointed.

 

    	 

    	 

    

 

6.
Effect of Merger on Capital Stock. At the Effective Time, all shares of capital stock of Ermis Labs issued to the Company
shall be cancelled and extinguished. The capital stock of the Company issued and outstanding immediately prior to the Effective
Time shall be unchanged and remain issued and outstanding immediately after consummation of the Merger.

 

7.
Amendment, Abandonment or Deferral. This Plan of Merger may be amended by the Board of Directors of the Company at any
time prior to the Effective Time. At any time before the Effective Time, this Plan of Merger may be terminated and the Merger
may be abandoned, or the consummation of the Merger may be deferred for a reasonable period of time if, in the opinion of the
Board of Directors of the Company, such action would be in the best interests of the Company. In the event of termination of this
Plan of Merger, this Plan of Merger shall become void and of no effect.

 

This
Plan of Merger has been adopted as of the date set forth above.

 

	 	ICTV
    Brands Inc.
	 	 	 
	 	By:	/s/
    Kelvin Claney
	 	Name:	Kelvin
    Claney
	 	Title:	Chief
    Executive Officerbiei_ex101.htm

EXHIBIT 10.1
  
 EXCHANGE AGREEMENT
  
 This Exchange Agreement (this “Agreement”) is entered into on August 8, 2017 by and between Premier Biomedical, Inc., a Nevada corporation (the “Company”) and [●] (the “Shareholder”). Any capitalized terms not defined herein shall have the meaning given to such term in the Securities Purchase Agreement.
  
 RECITALS
  
 WHEREAS, pursuant to a Securities Purchase Agreement by and between the Company and the Shareholder, dated March 30, 2017 (the “Securities Purchase Agreement”), the Shareholder agreed to purchase up to $200,000 of the Company’s securities including shares of common stock, Series A Common Stock Purchase Warrants (“Series A Warrants”) and Series B Common Stock Purchase Warrants (“Series B Warrants”);
  
 WHEREAS, in accordance with the Securities Purchase Agreement, the First Closing occurred on March 30, 2017 and the Shareholder purchased 13,333,334 shares of the Company’s common stock, 13,333,334 Series A Warrants and 13,333,334 Series B Warrants; 
  
 WHEREAS, in accordance with the Securities Purchase Agreement, the Second Closing occurred on May 30, 2017 and the Shareholder purchased 10,101,011 shares of the Company’s common stock, 10,101,011 Series A Warrants and 10,101,011 Series B Warrants; and
  
 WHEREAS, to better facilitate registration of the purchased securities under the Securities Act of 1933, as amended, the Shareholder and the Company now desire to effect the exchange of (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a convertible note issued by the Company, as set forth in Exhibit A hereto (the “Convertible Note”), as set forth herein. 
  
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Shareholder hereby agree as follows:
  
 AGREEMENT
  
 1. Exchange of Shares. The Shareholder hereby agrees to exchange the Exchange Securities for the Convertible Note effective upon the Company’s issuance of the Convertible Note to the Shareholder (the “Note Issuance”). The Exchange Securities shall be immediately cancelled with no further action by either party upon the effectiveness of the Note Issuance.
   	 
	1
	 
 
	 

  
 2. Representations and Warranties. The Shareholder represents to the Company as of the date hereof that (a) it will acquire the Convertible Note, and the shares of common stock issuable upon exercise of the Convertible Note (the “Conversion Shares”), for its account for the purpose of investment and not with a view to the distribution or resale thereof, (b) it has such knowledge and experience in financial and business matters that the Shareholder is capable of evaluating the merits and risks of acquiring the Convertible Note and Conversion Shares, and (c) the Shareholder understands the Convertible Note and Conversion Shares have not been registered under the Securities Act of 1933 or under any other securities law and, therefore, none of the Convertible Note or Conversion Shares can be sold, assigned, transferred, pledged or otherwise disposed of without registration under applicable securities laws or unless an exemption from such registration thereunder is available.
  
 3. Transfer Restrictions. The Convertible Note and Conversion Shares may not be sold, assigned, pledged, hypothecated or otherwise transferred except in accordance with applicable securities laws. The Company shall not be required (a) to transfer on its books any Convertible Note or Conversion Shares that have been sold or otherwise transferred in violation of the foregoing transfer restrictions or (b) to treat as the owner of such Convertible Note or Conversion Shares or to accord the right to vote or make distributions to any purchaser or other transferee to whom such Convertible Note or Conversion Shares shall have been so transferred. The Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records.
  
 4. Amendment; Waiver. No provision of this Agreement may be amended except by a written instrument signed by both parties. No provision of this Agreement may be waived except by a written instrument signed by the party against which such waiver is to be enforced. Except as expressly provided otherwise in a waiver, no such waiver shall constitute an ongoing or future waiver of any provision of this Agreement.
  
 5. Severability. Should any provision of this Agreement be found by a court of competent jurisdiction to be illegal or unenforceable, such provision shall be severed from this Agreement and the other provisions shall continue in full force and effect.
  
 6. Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same agreement. Facsimile copies of signed signature pages shall be binding originals for all purposes hereunder.
  
 7. Entire Agreement. This Agreement constitutes the entire agreement and understanding between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements, written or oral, between the parties with respect thereto.
  
 8. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York.
  
 [Remainder of page intentionally left blank, signature page to follow]
  
  	 
	2
	 
 
	 

  
 IN WITNESS WHEREOF, the parties have executed this Exchange Agreement as of the date first set forth above.
  
  	 “Company”
	  
	 “Shareholder”
	  

	  
		  
	  
	  
	  

	 Premier Biomedical, Inc.,
	  
	 [●]
	  

	 a Nevada corporation
	  
	  
		  

	  
		  
	  
		  

	  
		  
	  
		  

		  
	  
	  

	 By:
	 William A. Hartman
	  
	 By:
	 [●] 
	  

	 Its: 
	 Chief Executive Officer 
	  
	 Its:
	 [●]
	  

  
  	 
	3
	 
 
	 

  
 Exhibit A
  
 Convertible Note
  
  
  
  
  	 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]